PPD says new CEO's Pfizer experience will guide partnerships

By Gareth Macdonald

- Last updated on GMT

Related tags Contract research organization

PPD says new CEO's Pfizer experience will guide partnerships
US CRO Pharmaceutical Product Development (PPD) predicts that new CEO Dave Simmons' ‘pharmaceutical industry experience’ gained at Pfizer will be an asset in guiding partnerships.

The appointment comes five months after former CEO Raymond Hil​l ended his brief tenure at PPD following the firm’s acquisition by the Carlyle Group and Hellman & Friedman.

Simmons joins PPD from US drug giant Pfizer where he was responsible for the development of the firm’s established products and emerging markets business.

PPD spokesman Ned Glascock said the contract research organisation (CRO) ‘did not miss a beat’ during the CEO selection process and told Outsourcing-pharma.com that Simmons’ previous role and experience in the field of biosimilars and IT were key to winning him the job.

David’s extensive international experience, including with emerging markets, provides him with keen insight that will serve him well in guiding PPD’s delivery of quality services to our global clients​.”

We also asked if Simmons’ knowledge of Pfizer’s inner workings made it more likely PPD would do more work with the world’s largest drugmaker.

And – while he did not answer directly – Glascock did say that: “David’s extensive pharmaceutical industry experience, leadership and vision will be assets in guiding PPD’s partnerships with all of its valued clients​.”

Simmons will take over the top PPD job  on June 1 at which time Olivier Bandicourt - current Pfizer head of primary care – will take over as chief of the US drugmakers’ $16bn a year established products and emerging markets business.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars